Attached files
| file | filename |
|---|---|
| 10-K - ANNUAL REPORT - Citius Pharmaceuticals, Inc. | f10k2020_citiuspharma.htm |
| EX-32.1 - CERTIFICATION - Citius Pharmaceuticals, Inc. | f10k2020ex32-1_citius.htm |
| EX-31.2 - CERTIFICATION - Citius Pharmaceuticals, Inc. | f10k2020ex31-2_citius.htm |
| EX-31.1 - CERTIFICATION - Citius Pharmaceuticals, Inc. | f10k2020ex31-1_citius.htm |
| EX-21 - SUBSIDIARIES - Citius Pharmaceuticals, Inc. | f10k2020ex21_citius.htm |
| EX-10.24 - LICENSE AGREEMENT, DATED OCTOBER 6, 2020, BETWEEN NOVECITE, INC. AND NOVELLUS TH - Citius Pharmaceuticals, Inc. | f10k2020ex10-24_citius.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Forms S-1 (No.’s 333-224386, 333-226395, 333-230919, 333-233759, 333-237638 and 333-238975) and on Form S-3 (No. 333-248748) of Citius Pharmaceuticals, Inc. of our report dated December 16, 2020, relating to the consolidated financial statements of Citius Pharmaceuticals, Inc., appearing in the Annual Report on Form 10-K for the year ended September 30, 2020.
| /s/ Wolf & Company, P.C. | |
| Wolf & Company, P.C. | |
| Boston, Massachusetts | |
| December 16, 2020 |